LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 2 of 2: Mean cell count and mean normalized growth rate inhibition values across technical replicates. - Dataset (ID:20260)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol 1 Concentration | Small Mol 1 Conc Unit | Small Molecule 2 | Small Mol 2 Concentration | Small Mol 2 Conc Unit | Biological Replicate | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Dactolisib | 0.0137 | uM | Selumetinib | 0.1235 | uM | 2 | 1843 | 2754 | 5189 | 0.3074 |
| BT-20 | Dactolisib | 0.0137 | uM | Selumetinib | 0.3704 | uM | 2 | 1843 | 2524 | 5189 | 0.2331 |
| BT-20 | Dactolisib | 0.0137 | uM | Selumetinib | 1.1111 | uM | 2 | 1843 | 2264 | 5189 | 0.1475 |
| BT-20 | Dactolisib | 0.0137 | uM | Selumetinib | 3.3333 | uM | 2 | 1843 | 2212 | 5189 | 0.1296 |
| BT-20 | Dactolisib | 0.0137 | uM | Selumetinib | 10 | uM | 2 | 1843 | 2032 | 5189 | 0.0666 |
| BT-20 | Dactolisib | 0.0137 | uM | Lapatinib | 1.9245 | uM | 2 | 1843 | 3033 | 5189 | 0.3955 |
| BT-20 | Dactolisib | 0.0137 | uM | Lapatinib | 3.3333 | uM | 2 | 1843 | 3217 | 5189 | 0.4521 |
| BT-20 | Dactolisib | 0.0137 | uM | Lapatinib | 5.7735 | uM | 2 | 1843 | 3302 | 5189 | 0.4775 |
| BT-20 | Dactolisib | 0.0137 | uM | Lapatinib | 10 | uM | 2 | 1843 | 2629 | 5189 | 0.2641 |
| BT-20 | Dactolisib | 0.0137 | uM | NVP-TAE684 | 0.3704 | uM | 2 | 1843 | 3613 | 5189 | 0.5684 |
| BT-20 | Dactolisib | 0.0137 | uM | NVP-TAE684 | 1.1111 | uM | 2 | 1843 | 3110 | 5189 | 0.4177 |
| BT-20 | Dactolisib | 0.0137 | uM | NVP-TAE684 | 3.3333 | uM | 2 | 1843 | 1501 | 5189 | -0.1288 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 0.0713 | uM | 2 | 1843 | 2775 | 5189 | 0.3118 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 0.1235 | uM | 2 | 1843 | 2766 | 5189 | 0.3107 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 0.2138 | uM | 2 | 1843 | 2497 | 5189 | 0.2210 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 0.3704 | uM | 2 | 1843 | 2147 | 5189 | 0.1071 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 0.6415 | uM | 2 | 1843 | 2109 | 5189 | 0.0938 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 1.1111 | uM | 2 | 1843 | 2065 | 5189 | 0.0780 |
| BT-20 | Dactolisib | 0.0137 | uM | Neratinib | 1.9245 | uM | 2 | 1843 | 1928 | 5189 | 0.0291 |
| BT-20 | Dactolisib | 0.0137 | uM | Saracatinib | 0.2138 | uM | 2 | 1843 | 2887 | 5189 | 0.3488 |
| BT-20 | Dactolisib | 0.0137 | uM | Saracatinib | 0.3704 | uM | 2 | 1843 | 2963 | 5189 | 0.3735 |
| BT-20 | Dactolisib | 0.0137 | uM | Saracatinib | 0.6415 | uM | 2 | 1843 | 2881 | 5189 | 0.3476 |
| BT-20 | Dactolisib | 0.0137 | uM | Saracatinib | 1.1111 | uM | 2 | 1843 | 2504 | 5189 | 0.2275 |
| BT-20 | Dactolisib | 0.0137 | uM | Saracatinib | 1.9245 | uM | 2 | 1843 | 2443 | 5189 | 0.2062 |
| BT-20 | Dactolisib | 0.0137 | uM | Saracatinib | 3.3333 | uM | 2 | 1843 | 2236 | 5189 | 0.1378 |